Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model

被引：3
|
作者：
Green, Damian J.
Jones, Jon C.
Hylarides, Mark D.
Hamlin, Donald K.
Wilbur, D. Scott
Lin, Yukang
Kenoyer, Aimee L.
Frayo, Shani L.
Bensinger, William I.
Gopal, Ajay K.
Orozco, Johnnie J.
Gooley, Theodore A.
Wood, Brent L.
Pagel, John M.
Press, Oliver W.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.882.882
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
882
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
    McNamara, S.
    Chorazy, J.
    Pandey, A.
    Bitetti, J.
    Boytsov, N.
    Purser, M.
    Iheanacho, I.
    VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
  • [42] Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
    Tan, Chia Jie
    Kacerek, Dylan
    Kampirapawong, Nattawara
    Godara, Amandeep
    Chaiyakunapruk, Nathorn
    CANCER MEDICINE, 2025, 14 (05):
  • [43] Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Diamond, Benjamin
    Bolli, Niccolo
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    BLOOD, 2023, 142
  • [44] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Oses, Lucrecia
    Brulc, Erika
    Carretero, Marcelina
    Nucifora, Elsa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [45] Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
    Caroni, Federico
    Sammartano, Vincenzo
    Pacelli, Paola
    Sicuranza, Anna
    Malchiodi, Margherita
    Dragomir, Andreea
    Ciofini, Sara
    Raspadori, Donatella
    Bocchia, Monica
    Gozzetti, Alessandro
    PHARMACEUTICALS, 2025, 18 (02)
  • [46] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
  • [47] COST OF ANTI-CD38 MONOCLONAL ANTIBODIES IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
    Lin, P.
    Petitjean, A.
    Drea, E.
    Lin, F.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [48] High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Roussou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S154
  • [49] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhe Zhu
    Kairui Hong
    Yefang Ke
    Annals of Hematology, 2023, 102 : 1961 - 1962
  • [50] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhu, Zhe
    Hong, Kairui
    Ke, Yefang
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1961 - 1962
12345